背景:泪液,多汗症,腋臭,和背汗症是严重影响患者健康和生活质量的常见腺体疾病。肉毒杆菌毒素通过靶向副交感神经胆碱能神经元,可以安全地暂时减少腺体分泌,导致唾液和汗液分泌减少。
目的:本文的目的是描述神经调质在唾液治疗中的应用,eccrine,和大汗腺.
方法:PubMed从开始到2024年2月1日使用搜索词“神经毒素,肉毒杆菌毒素,\"\"流涎,\"\"多汗症,\"\"腋臭,“和”发汗症。\"
结果:IncobotulinumtoxinA和RimabotulinumtoxinB被FDA批准用于治疗鼻漏。OnabotulinumtoxinA是FDA批准的唯一用于腋窝多汗症的肉毒毒素,用于非腋窝部位的多汗症。腋臭,和色汗症。与A型肉毒杆菌毒素相比,血清型B与更多的免疫原性相关,这可能对需要长期治疗慢性腺体疾病的患者有影响。
结论:神经调质对于腺体活动过多的非侵入性治疗是安全有效的,可以改善患者的生活质量。虽然大量文献支持肉毒杆菌毒素治疗多汗症,需要进一步的研究来描述标准的给药和给药技术,腋臭,和色汗症。
BACKGROUND: Sialorrhea, hyperhidrosis, bromhidrosis, and chromhidrosis are common glandular disorders that substantially impact patients\' health and quality of life. Botulinum toxin can safely and temporarily decrease gland secretions by targeting the parasympathetic cholinergic neurons, resulting in diminished saliva and sweat production.
OBJECTIVE: The objective of this article is to describe the applications of neuromodulators for the treatment of salivary, eccrine, and apocrine glands.
METHODS: PubMed was searched from inception to February 1, 2024 using search terms \"neurotoxin,\" \"botulinum toxin,\" \"sialorrhea,\" \"hyperhidrosis,\" \"bromhidrosis,\" and \"chromhidrosis.\"
RESULTS: Incobotulinumtoxin A and Rimabotulinumtoxin B are approved by the FDA for the treatment of sialorrhea. Onabotulinumtoxin A is the only FDA-approved botulinum toxin for axillary hyperhidrosis and is used off-label for hyperhidrosis of nonaxillary sites, bromhidrosis, and chromhidrosis. Compared to botulinum toxin serotype A, serotype B has been associated with more immunogenicity, which may have implications for patients requiring long-term treatment for chronic glandular disorders.
CONCLUSIONS: Neuromodulators are safe and effective for the noninvasive treatment of excess gland activity and can improve patients\' quality of life. While substantial literature supports botulinum toxin treatments for hyperhidrosis, further studies are needed to characterize standard dosing and administration techniques for sialorrhea, bromhidrosis, and chromhidrosis.